Option chain shows key data for Longeveron's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Longeveron.

Longeveron (NASDAQ:LGVN) Stock, Option Chain

LONGEVERON INC-A

Longeveron

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Screenshot 2024-11-15 at 7.50.34 PM

Biotech

General

BCLI

BRTX

LGVN

MESO

Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative&#39;s Inroads Bringing Its Stem Cell Therapies To Market

movers image

News

Pre-Market Outlook

Movers

ADSE

ARBB

EONR

HCTI

IBRX

INDO

JFBR

JTAI

LENZ

MNPR

NWTN

PXDT

TARS

TCBP

TVGN

UPXI

Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Digital,Marketing,Data,Analytic,Technology,,Businessman,Using,Laptop,Computer,To

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

CRWD

KOSS

MIRA

MSFT

NUZE

NVDA

PLTR

SERV

SMCI

SOBR

TSLA

ZAPP

A look at the most-searched tickers on Benzinga Pro for the month of July shows some familiar names like Tesla, Nvidia and Apple. Here&#39;s a look at the others.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?

Longeveron Inc

Press Releases

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Health Care

Longeveron® Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Earnings

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease

AEMD

ANPCY

ASPI

ATWT

BDRX

BENF

BIXT

BNRG

BOSC

CSE:HG

ELRRF

GOSS

GOVX

HDRSF

HGRAF

IMRN

IPWR

JAGX

PBEGF

RGBP

SIGY

TSX:CNL

TSX:ELO

TSX:TXP

TSXV:HI

TSXV:WRLG

UCAR

USEG

WRLGF

XXII

Abpro Hldgs

Allakos

BioAtla

BioVie

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

CEL-SCI

Cyclo Therapeutics

Equillium

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

OSR Holdings

Ovid Therapeutics

Passage Bio

Pluri

Q32 Bio

Rallybio

Tenax Therapeutics

Unity Biotechnology

HC Wainwright & Co.

Roth MKM

Maxim Group

EF Hutton

Comments

Longeveron

Longeveron (LGVN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga